Cellectis (CLLS) Operating Leases (2018 - 2026)
Cellectis' (CLLS) quarterly Operating Leases came in at $25.9 million in Q1 2026, down 21.7% year-on-year from $33.1 million in Q1 2025, and down 6.41% quarter-over-quarter from $27.7 million in Q4 2025.
Cellectis (CLLS) Operating Leases (2018 - 2026) Analysis & Trends
Cellectis' Operating Leases history runs 9 years deep, the most recent figure standing at $25.9 million for Q1 2026.
- On a quarterly basis, Operating Leases fell 21.7% year-over-year to $25.9 million in Q1 2026; TTM through Mar 2026 was $25.9 million, a 21.7% decrease from a year earlier, with the FY2025 full-year figure at $27.7 million, down 19.04% from the prior year.
- Operating Leases slipped to $25.9 million in Q1 2026 per CLLS's latest filing, from $27.7 million in the prior quarter.
- Across five years, Operating Leases topped out at $69.7 million in Q1 2022 and bottomed at $25.9 million in Q1 2026.
- The 5-year median for Operating Leases is $40.6 million (2024), against an average of $42.9 million.
- Across the five-year window, Operating Leases slipped 4.99% in 2022 and slumped 31.1% in 2023, its largest moves.
- Year by year, Operating Leases stood at $49.4 million in 2022, then declined by 12.99% to $42.9 million in 2023, then slipped by 20.26% to $34.2 million in 2024, then slipped by 19.04% to $27.7 million in 2025, then retreated by 6.41% to $25.9 million in 2026.
- Per Business Quant, the three latest CLLS Operating Leases figures stand at $25.9 million (Q1 2026), $27.7 million (Q4 2025), and $29.3 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - |
| 10 | Cellectis | 281.48 Mn | 95.81 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 25.95 Mn |
| Dec 31, 2025 | 27.73 Mn |
| Sep 30, 2025 | 29.25 Mn |
| Jun 30, 2025 | 32.26 Mn |
| Mar 31, 2025 | 33.14 Mn |
| Dec 31, 2024 | 34.25 Mn |
| Sep 30, 2024 | 36.68 Mn |
| Jun 30, 2024 | 38.36 Mn |
| Mar 31, 2024 | 40.59 Mn |
| Dec 31, 2023 | 42.95 Mn |
| Sep 30, 2023 | 43.82 Mn |
| Jun 30, 2023 | 46.16 Mn |
| Mar 31, 2023 | 48.29 Mn |
| Dec 31, 2022 | 49.36 Mn |
| Sep 30, 2022 | 63.59 Mn |
| Jun 30, 2022 | 66.59 Mn |
| Mar 31, 2022 | 69.74 Mn |
| Dec 31, 2021 | 71.53 Mn |
| Sep 30, 2021 | 73.73 Mn |
| Jun 30, 2021 | 75.76 Mn |